Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis

Advances in Therapy

Volumn 28, Issue 7, 2011, Pages 566-574

  Tauber, Shachar ^a   Cupp, Gale ^b   Garber, Richard ^b   Bartell, John ^b   Vohra, Firoz ^b   Stroman, David ^b  

^a St John's Hospital   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Bacterial conjunctivitis; Fluoroquinolone; Microbial efficacy; Moxifloxacin; Ophthalmic solution

Indexed keywords

MOXIFLOXACIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL CONJUNCTIVITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EVENING DOSAGE; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MORNING DOSAGE; MULTICENTER STUDY; OINTMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PNEUMOCOCCAL INFECTIONS; QUINOLINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 82455167897     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0037-x     Document Type: Article

References (12)

1. Drancourt M, Herbert L. Conjunctivitis, keratitisand infections of periorbital structures. In: CohenJ, Powderly WG, Opal SM, eds. Cohen & Powderly: Infectious Diseases. 3 ed. Mosby, an Imprint of Elsevier, Inc.; 2010.
2. Buznach N, Dagan R, Greenberg D. Clinicaland bacterial characteristics of acute bacterialconjunctivitis in children in the antibiotic resistanceera. Pediatr Infect Dis J. 2005;24: 823-828. (Pubitemid 41324892)
3. Ohnsman CM. Exclusion of students with conjunctivitis from school: Policies of statedepartments of health. J Pediatr OphthalmolStrabismus. 2007;44: 101-5. (Pubitemid 46663724)
4. Lichtenstein SJ, Dorfman M, Kennedy R, StromanD. Controlling contagious bacterial conjunctivitis.J Pediatr Ophthalmol Strabismus. 2006;43: 19-26. (Pubitemid 43188264)
5. CDC. Outbreak of bacterial conjunctivitis at acollege -New Hampshire, January-March, 2002. MMWR Morb Mortal Wkly Rep. 2002;51: 205-207.
6. CDC. Pneumococcal conjunctivitis at an elementary school -Maine, September 20-December 6, 2002. MMWR Morb Mortal Wkly Rep. 2002;52: 64-66.
7. Martin M, Turco JH, Zegans ME, et al. An outbreakof conjunctivitis due to atypical Streptococcuspneumoniae. N Engl J Med. 2003;348: 1112-1121. (Pubitemid 36337322)
8. D'Arienzo PA, Wagner RS, Jamison T, Bell B, Dajcs JJ, Stroman DW. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positiveconjunctival pathogens. Adv Ther 2010;27: 39-47.
9. Wagner RS, Granet DB, Lichtenstein SJ, et al.Kinetics of kill of bacterial conjunctivitis isolateswith moxifloxacin, a fluoroquinolone, comparedwith the aminoglycosides tobramycin andgentamicin. Clin Ophthalmol. 2010;4: 41-45.
10. Sheikh A, Hurwitz B. Antibiotics versus placebo foracute bacterial conjunctivitis. Cochrane DatabaseSyst Rev 2006;CD001211.
11. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacinand moxifloxacin ophthalmic solution 0.5%, anew topical fluoroquinolone. Surv Ophthalmol. 2005;50(Suppl. 1): S16-S31. (Pubitemid 41657596)
12. Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008;86: 5-17. (Pubitemid 351512464)